<DOC>
	<DOCNO>NCT02010034</DOCNO>
	<brief_summary>This study do determine investigational study drug call Omegaven help improve liver disease think cause Total Parenteral Nutrition ( TPN ) . TPN intravenous feeding ( IV feed tube ) provide patient nutrient unable drink fluid eat food mouth .</brief_summary>
	<brief_title>Compassionate Use Omegaven Treatment Parenteral Nutrition Induced Hepatic Injury</brief_title>
	<detailed_description>PAtients direct bilirubin &gt; 2gm/dL short bowel syndrome eligible enrollment . Omegaven 1gm/kg/day administered via central venous line instead standard lipid preparation .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>1 . Patients must 2 month 10 year age 2 . Patients PN dependent ( unable meet nutritional need solely enteral nutrition ) expect require PN least another 30 day 3 . Patients consider eligible study participation must parenteral nutrition associate liver disease ( PNALD ) define direct bilirubin &gt; 2.0mg/dL . Other cause liver disease exclude . A liver biopsy necessary treatment 4 . 2 consecutive direct bilirubin test result &gt; 2.0mg/dl 5 . The patient must fail standard therapy prevent progression liver disease surgical treatment , cyclic TPN , avoid overfeeding , reduction/removal copper manganese TPN , advancement enteral feeding , use ursodiol ( Actigall ) 6 . Subjects currently treatment PNALD Compassionate Use Omegaven direct Bilirubin &lt; 2 , remain TPN dependent require continue therapy Omegaven 1 . Other known cause chronic liver disease ( hepatitis C , cystic fibrosis , biliary atresia alpha 1 antitrypsin deficiency ) 2 . Enrollment clinical trial involve investigational agent ( unless approve designated physician multidisciplinary team ) 3 . The parent , guardian , child unwilling provide consent assent 4 . Allergy fish product , egg protein , and/or previous allergy Omegaven 5 . Active coagulopathies characterize ongoing bleed requirement clot factor replacement fresh frozen plasma cryoprecipitate maintain homeostasis 6 . Impaired lipid metabolism severe hyperlipidemia without pancreatitis 7 . Unstable diabetes mellitus 8 . Stroke/embolism 9 . Collapse shock 10 . Undefined coma status 11 . Active infection time initiation OmegavenÂ® time child afebrile stable vital sign one negative 48 hour culture</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TPN</keyword>
	<keyword>Liver Function</keyword>
	<keyword>parenteral nutritional fat emulsion</keyword>
</DOC>